91 KB13 KB192920262004Grat, MatejaVučković, Joškostr. I-31 - I-33ISSN:1318-0347COBISSID_HOST:196003URN:URN:NBN:SI:doc-HXL70SIIslSlovensko zdravniško društvoZdravniški vestnikAdverse effectsDrug therapyLeukemia, myeloidLevkemija, mieloidnaMethyl MethanesulfonateMetil metansulfonatNeželeni učinkiTherapeutic useUporaba za zdravljenjeZdravljenje z zdraviliNaše izkušnje pri zdravljenju kronične mieloične levkemije z imatinib mesilatom| Treatment with imatinib mesilat in chronic myelogenous leukemia - our experience|Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hamatopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9,22) which result in fusion oncoprotein with tyrosine kinase activity. The normal ABL protein is involved in the regulation of the cell cycle. Fusion oncoprotein deregulates signal transducing pathways, causing an abnormal cell cycling, inhibition of apoptosis and increased proliferation of cells. ABL specific tyrosin kinase inhibitors selectively inhibit the growth of BCR-ABL positive cells. Methods. eleven patients with chronic phase CML were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses and toxic effects. Results. Imatinib induced major cytogenetic response (MCR) in 78% and a complete hematologic response (CHR) in 100% of eleven patients. We observe non hematologic toxic effects in 55% and grade 3 or 4 hematologic toxic effects in 11% of patients. Conclusions. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic phase CMLIzhodišča. Kronična mieloična levkemija (KML) je maligna klonska bolezen krvotvornih matičnig celic. Pri večini bolnikov najdemo recipročno translokacijo t (9,22), katere posledica je BCR-ABL onkogen in onkoprotein z aktivnostjo tirozin kinaze. Posledično nastopi deregulacija poti signalne transdukcije z motnjami celičnega cikla, inhibicijo apoptoze in proliferacijo celic. ABL specifični zaviralci tirokin kinaze selektivno zavro proliferacijo malignega klona. Metode. Pri 11 bolnikih v kronični fazi KML smo uvedli imatinib 400 mg dnevno. Ocenjevali smo citogenski in hematološki odgovor ter pojavljanje neželenih učinkov zdravila. Rezultati. Z imatinibom smo dosegli dober citogenski odgovor pri 78% bolnikov, od tega pri 11% popoln citogenski odgovor. Pri vseh bolnikih je bila dosežena popolna hematološka remisija 4 tedne po uvedbi zdravila. Neželene učinke smo opazovali pri 55% bolnikov, resnejše hematološke neželene učinke pa pri 11% bolnikov. Zaključki. Pri zdravljenju bolnikov v kronični fazi KML z imatinibom smo dosegli dober citogenetski in popoln hematološki odgovorTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo